Goserelin Acetate inj
Phase 3Small molecule
Goserelin Acetate inj is one of 2 small molecule programs targeting Metabolic Dysfunction-Associated Steatotic Liver Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Metabolic Dysfunction-Associated Steatotic Liver Disease
#DrugCompanyPhaseTrials
1Iglarlixi
SanofiPhase 3
Goserelin Acetate inj
AAristotle University Of Thessaloniki
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Goserelin Acetate inj. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details